BioAge Labs (NASDAQ:BIOA) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a strong sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the company. Weiss Ratings downgraded BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a report on Tuesday, September 8th. Needham & Company LLC cut their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research note on Friday, July 31st. Finally, Roth Capital reiterated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a research note on Wednesday, September 9th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, BioAge Labs has a consensus rating of “Moderate Buy” and an average target price of $33.00.

BioAge Labs Trading Down 6.3%

BioAge Labs stock opened at $5.94 on Friday. BioAge Labs has a 12-month low of $5.04 and a 12-month high of $25.95. The firm has a 50-day moving average price of $8.87 and a 200-day moving average price of $15.46. The firm has a market capitalization of $272.65 million, a PE ratio of -2.50 and a beta of 1.08.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. As a group, sell-side analysts predict that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of BioAge Labs during the 2nd quarter worth $69,831,000. Jupiter Topco LLC bought a new stake in shares of BioAge Labs in the second quarter valued at about $52,597,000. Janus Henderson Group PLC raised its holdings in shares of BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after acquiring an additional 1,685,063 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in shares of BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in BioAge Labs in the second quarter worth about $8,686,000.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.